Meeting
2023 ASCO Annual Meeting
Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles.
Authors
Anumita Chakraborty
Temple University Health System, Philadelphia, PA
Anumita Chakraborty , Jill S Hasler , Elizabeth A. Handorf , Fern Anari , Pooja Ghatalia , Benjamin Miron , Elizabeth R. Plimack , Daniel M. Geynisman , Matthew R. Zibelman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4586)
DOI
10.1200/JCO.2023.41.16_suppl.4586
Abstract #
4586
Poster Bd #
78
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder.
First Author: Amarnath Challapalli
Poster
2024 ASCO Breakthrough
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined with immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study.
First Author: Jiao Hu
Poster
2024 ASCO Genitourinary Cancers Symposium
Pathologic and survival outcomes following radical cystectomy for “progressive” and “de novo” muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
First Author: Leilei Xia
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes with neoadjuvant chemotherapy in bladder-preserving treatment for MIBC.
First Author: Michael Glover